Journal: Oncotarget

Article Title: A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide

doi:

Figure Lengend Snippet: (A) qPCR confirming the overexpression of HOXA9 in hTERT/E6/E7-HOXA9 and U87MG-HOXA9 cells and HOXA9 -silencing in U251-shHOXA9 and GBML18-shHOXA9 cells, comparing to their respective control counterparts. (B) Venn diagram summarizing the number of differentially expressed transcripts in the microarray data in all cell lines. The numbers in each area represent the total number of transcripts within each intersection. (C–F) DAVID was used to query the HOXA9-transcriptome from each cell line (C, hTERT/E6/E7; D, U87MG; E, U251; F, GBML18), in order to identify enriched biological terms on the differentially expressed genes extracted from the microarray data. Statistically significant enriched GO terms are shown for each cell line.

Article Snippet: For HOXA9 silencing , GBML18 and U251 cells were transfected with pGFP-V-RS plasmid containing HOXA9-specific shRNAs or non-effective shRNAs sequences (Origene).

Techniques: Over Expression, Microarray

Journal: Oncotarget

Article Title: A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide

doi:

Figure Lengend Snippet: (A–D) GSEA reveals that the HOXA9 transcriptomes in hTERT/E6/E7 (A) and U251 (C) cells are associated with transcriptional signatures of glioma stem-like cells (Enrichment Score, ES = −0.54, False Discovery Rate, FDR = 0.19; and ES = 0.50, FDR = 0.11, respectively); in U87MG cells (B) , the HOXA9 transcriptome is positively associated with genes that are upregulated in embryonic stem cells (ES = 0.50, FDR < 0.0001); in GBML18 cells (D) , HOXA9 transcriptome is inversely associated with genes upregulated during the neuronal differentiation (ES = 0.75, FDR = 0.21). (E) Representative phase contrast photographs of hTERT/E6/E7 and U87MG neurospheres are shown. (F) Quantification of neurospheres number and size for each cell line ( n = 3; * p < 0.05; *** p < 0.001). (G) Immunofluorescence showing increased Nestin staining in HOXA9-positive cells.

Article Snippet: For HOXA9 silencing , GBML18 and U251 cells were transfected with pGFP-V-RS plasmid containing HOXA9-specific shRNAs or non-effective shRNAs sequences (Origene).

Techniques: Immunofluorescence, Staining

Journal: Oncotarget

Article Title: A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide

doi:

Figure Lengend Snippet: (A and B) Determination of the half inhibitory concentration (IC 50 ) values after 6 days of temozolomide (TMZ) treatment in HOXA9 -positive or HOXA9 -negative hTERT/E6/E7 and U87MG (A), and HOXA9 -silenced or control U251 and GBML18 (B) cell lines. (C–F) Cell viability trypan blue assays in HOXA9 -negative/low or HOXA9 –positive/high hTERT/E6/E7 (C), U87MG (D), U251 (E) and GBML18 (F) cells, exposed to temozolomide or vehicle. (G) Cell death was evaluated by annexin V staining followed by flow cytometry in HOXA9 -positive/high and HOXA9 -negative/low hTERT/E6/E7, U87MG, U251 and GBML18 cell lines, both in basal conditions and after exposure to temozolomide (TMZ). HOXA9 expression decreases cell death of all GBM cell models, both in basal conditions and after TMZ treatment, except in basal conditions for U251 cell line. (H) Cell invasion in the same cell lines, both in basal conditions and after exposure to TMZ. HOXA9 increases the invasion of hTERT/E6/E7, U87MG, and GBML18 cells. U251 cells did not show significant differences in invasion profiles due to HOXA9 levels or TMZ treatment. Results are representative of at least three independent experiments, performed in triplicates (data points represent mean ± SEM). Statistical differences were calculated by Student's t -test (panels A, B, G, H) and two-way ANOVA (panels C–F) (* p < 0.05; ** p < 0.01; *** p < 0.001).

Article Snippet: For HOXA9 silencing , GBML18 and U251 cells were transfected with pGFP-V-RS plasmid containing HOXA9-specific shRNAs or non-effective shRNAs sequences (Origene).

Techniques: Concentration Assay, Staining, Flow Cytometry, Expressing

Journal: Translational Oncology

Article Title: Global Conservation of Protein Status between Cell Lines and Xenografts 1

doi: 10.1016/j.tranon.2016.05.005

Figure Lengend Snippet: Comparison of In Vitro and In Vivo Data for Each Model

Article Snippet: SNB19 glioma cell line was given by N. Auger (Institut Curie, Paris, France).

Techniques: Comparison, In Vitro, In Vivo